retatrutide phase 2 trial obesity nejm 2023 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis 🤔 Adults with type 2

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire

Using a pen that delivers 1 mg or 2 mg doses when prescribed 0.25 mg or 0.5 mg results in significant overdosing

Simple, honest statements work well: you had a late lunch and want something light, your stomach has been sensitive so you're keeping it simple, or you're pacing yourself throughout the day

Bachem AG

With todays advanced, research-driven optionsSculptra, hyaluronic acid fillers, GLP-1tested skincare, and surgical rejuvenationwe can restore balance, volume, and radiance in a way that feels entirely you

Advances in the field of weight loss drugs are evolving rapidly